No Matched Donor for a Bone Marrow Transplant? How a Half-Matched Transplant Works

The doctor explained that a bone marrow transplant offers the best chance of a cure. Then came the tests. Your brother is not a match. Your sister is not a match. The international registry search came back with nothing suitable. The words you heard next were “we will keep looking.”

For many families, especially those of African, Middle Eastern, South Asian or mixed heritage, that search can go on for months that the patient does not have. There is another option that many families are never told about clearly.

A haploidentical (half-matched) bone marrow transplant uses stem cells from a family member who shares half of the patient’s tissue type. Parents and children are always a half match, and each brother or sister has a 50% chance. With modern techniques, especially post-transplant cyclophosphamide, survival after a half-matched transplant is now similar to a fully matched unrelated donor transplant for many blood cancers.

This guide explains why full matches are hard to find, what “half-matched” really means, how results compare, how doctors pick the best family donor, and how to plan the transplant from abroad. It is written to help you ask the right questions, not to replace your transplant team’s advice on your specific case.

Why So Many Patients Never Find a Full Match

Before a transplant, doctors compare the patient’s and donor’s HLA (human leukocyte antigen) markers. These are proteins on the surface of cells that the immune system uses to tell “self” from “foreign.” The closer the HLA match, the lower the risk that the new immune system attacks the patient’s body, or that the patient’s body rejects the new cells.

You inherit one set of HLA markers from your mother and one from your father. That simple rule explains most of what families experience:

• A full brother or sister has only a 25% chance of being a full match. Many patients have no matched sibling at all, especially in smaller families.
• Unrelated donor registries work well for some groups and poorly for others. The largest US registry, NMDP, reports that only about two in three patients overall find a fully matched (8 out of 8) donor, and patients from diverse ethnic backgrounds have historically had less than a 50% chance.
• Registries are thin for many regions. Patients from sub-Saharan Africa, the Middle East, North Africa, South Asia and the Pacific Islands are underrepresented, so their search often returns no match or only a partial one.
• Time matters. Even when a registry donor is found, confirming, testing and collecting from that donor can take two to three months. In acute leukemia, that delay can allow the disease to return.

This is the gap the half-matched transplant fills.

What “Half-Matched” Actually Means

A haploidentical donor shares exactly one of the two HLA sets, the half inherited from one parent. Almost every patient has at least one such relative.

This means a family that was told “no donor found” may in fact have several possible donors sitting in the same room. The question shifts from “is there a donor?” to “which family donor is best?”

Why Half-Matched Transplants Now Work: The Post-Transplant Cyclophosphamide Breakthrough

Twenty years ago, half-matched transplants were risky. Mismatched immune cells from the donor often attacked the patient’s organs (graft-versus-host disease, or GVHD), and many grafts failed. Doctors tried removing immune cells from the graft in the lab, but that left patients exposed to serious infections.

The turning point came from researchers at Johns Hopkins, who developed a method called post-transplant cyclophosphamide (PTCy). It works in a surprisingly simple way:

1. The patient receives the donor’s stem cells (Day 0).
2. Over the next few days, the donor immune cells that recognize the patient as “foreign” start multiplying quickly.
3. On about Days 3 and 4, the patient receives high doses of a chemotherapy drug, cyclophosphamide. It destroys those rapidly dividing, reactive cells.
4. The blood-forming stem cells, which are protected from the drug, survive and go on to rebuild the patient’s blood and immune system.

In effect, PTCy removes most of the “dangerous” donor cells inside the body while keeping the cells the patient needs. It uses an inexpensive, widely available drug and needs no special laboratory processing. That is a major reason half-matched transplants have spread quickly in countries like India, where they are now performed routinely at experienced centers.

Half-Matched vs Other Donor Options

Large registry studies support this picture. A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis of adults with acute lymphoblastic leukemia in remission found that survival after half-matched transplant with PTCy was similar to matched sibling and fully matched unrelated donor transplants, with less severe GVHD than matched unrelated transplants. Similar findings have been reported in acute myeloid leukemia and lymphoma.

A matched sibling is still generally preferred when one exists. But when there is no matched sibling, a half-matched family donor is now a standard option, not a last resort.

Which Conditions Can Be Treated With a Half-Matched Transplant

Half-matched transplants are used for most conditions that need a transplant from another person (an allogeneic transplant):

• Blood cancers: Acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), chronic myeloid leukemia that no longer responds to tablets, and relapsed Hodgkin and non-Hodgkin lymphoma.
• Bone marrow failure:Severe aplastic anemia, especially when there is no matched sibling.
• Inherited blood disorders:Thalassemia major and sickle cell disease, where a transplant can be curative.
• Immune deficiency and other rare inherited disorders in children.

Results are not equal across all conditions, and an honest center will tell you this. For blood cancers in remission, outcomes are well established. For thalassemia and aplastic anemia, the main challenge has been graft rejection, because many of these patients have received a large number of blood transfusions over the years. Experienced centers use extra treatment before the transplant (sometimes called pre-transplant immunosuppression) and careful donor antibody testing to reduce this risk. This is one area where the center’s specific experience matters a great deal.

Half-matched transplants are generally not used for conditions treated with the patient’s own stem cells (an autologous transplant), such as most cases of multiple myeloma.

Choosing the Best Family Donor

When several relatives are half matches, doctors do not simply pick the first one tested. They rank donors using several factors. This is the part of the process families most often misunderstand.

(1) Donor-specific antibodies (DSA). This is often the most important factor. Some patients carry antibodies against particular HLA markers. If those antibodies target the donor’s markers, the graft is much more likely to fail. These antibodies are more common in:

• Women who have been pregnant, especially more than once
• Patients who have had many blood or platelet transfusions, such as those with thalassemia or aplastic anemia
• Patients who have had a previous transplant

The patient’s blood is tested for DSA against each possible donor. A donor the patient has strong antibodies against is usually avoided. When no other donor is available, some centers can lower the antibodies before transplant (desensitization).

(2) Donor age. Younger donors are generally preferred. A 2025 study from MD Anderson Cancer Center of 855 transplants using PTCy found that donor age affected survival more than donor type, with donors over 50 linked to higher risk than donors under 30. This is why a healthy adult son, daughter or younger sibling is often preferred over a parent in their 60s.

(3) Donor sex and relationship. Many centers prefer male donors or younger relatives over mothers who have had several pregnancies, partly because of antibody risk. For a child patient, a parent is often the most practical choice.

(4) Donor health. The donor needs a full medical check, including blood tests, infection screening, heart assessment and, in some cases, a chest X-ray. Conditions such as uncontrolled diabetes, heart disease or certain infections can rule a donor out.

(5) CMV status and blood group. Doctors consider whether the donor and patient have had cytomegalovirus (CMV), a common virus. Blood group is also noted, but a blood group mismatch does not prevent a transplant.

Practical tip for families: test several relatives early. HLA typing can often be done in your home country through a cheek swab or blood sample, and the results can be shared with the transplant center before you travel. This saves weeks.

What the Donor Goes Through

Many donors worry about the procedure, and some families hesitate to ask an elderly parent or young adult child. Donation is usually safe and short.

1. Evaluation (about 3 to 5 days): HLA confirmation, blood tests, infection screening, heart tests and a consultation with the transplant doctor.
2. Mobilizing stem cells (about 4 to 5 days): daily injections of a growth factor called G-CSF move stem cells from the bone marrow into the blood. Bone pain, tiredness and mild flu-like symptoms are common and usually settle with simple painkillers.
3. Collection (about 4 to 6 hours, sometimes over 2 days): the most common method, called apheresis, is similar to a long blood donation. Blood is drawn from one arm, stem cells are separated by a machine, and the rest of the blood is returned through the other arm. Less often, marrow is taken directly from the hip bone under anesthesia.
4. Recovery: most donors feel normal within a few days. The donor’s body replaces the stem cells naturally.

For international patients, the donor must travel to India with the patient for evaluation and collection. Many centers prefer the donor to stay until the patient’s new cells have started working (engraftment), in case extra cells are needed. Hospitals also usually ask for official proof of the family relationship, so prepare these documents early.

Risks to Discuss Openly

A half-matched transplant is a major treatment. Understanding the risks helps families make an informed choice and recognize problems early.

• Graft failure: the donor cells do not take hold. This is uncommon at experienced centers but more likely in heavily transfused patients and those with donor-specific antibodies. A second transplant, sometimes from a different family donor, may be possible.
• Graft-versus-host disease (GVHD): donor immune cells attack the skin, gut or liver. PTCy has greatly reduced severe GVHD, but some patients still develop it and need treatment, sometimes for months.
• Infections: the immune system takes months to rebuild. Viral infections such as CMV and BK virus, as well as bacterial and fungal infections, are closely monitored.
• Cyclophosphamide side effects: including fluid retention and, less often, bladder irritation or effects on the heart. These are watched for during the first weeks.
• Relapse: in blood cancers, the disease can return. The donor’s immune cells help protect against this (the “graft-versus-leukemia” effect).
• Long-term effects: fertility, hormones and growth in children need follow-up. Fertility preservation should be discussed before treatment.

Why Families Travel to India for a Half-Matched Transplant

India has become one of the world’s most active countries for half-matched transplants, for reasons that matter to international families:

1. Volume and experience: large Indian transplant centers perform haploidentical transplants routinely, including in children with thalassemia and aplastic anemia, the groups where experience matters most.
2. Speed: there is no wait for an overseas registry donor. Once the family donor is confirmed and the patient is fit, the transplant can usually be planned within weeks.
3. Cost: a half-matched transplant in India typically costs a fraction of the price in the US, UK or Gulf countries.
4. Access: many countries in Africa, the Middle East and the Pacific have few or no centers offering this transplant.

What to check before choosing a center:

• How many haploidentical transplants does the center perform each year, and for your condition specifically?
• Does it test for donor-specific antibodies, and can it manage desensitization if needed?
• Does it have HEPA-filtered transplant rooms and a dedicated BMT intensive care team?
• What are its results for your condition and age group?
• Is there an accreditation such as NABH or JCI, and a pediatric transplant unit for children?
• What follow-up support is offered after you return home?

Timeline: How Long You Will Stay in India

Every plan differs, but a typical half-matched transplant journey looks like this:

In total, most international patients should plan to stay about three months in India, with a caregiver throughout. The hospital stay itself is usually around three to five weeks. For detailed advice on the months after transplant, see our bone marrow transplant recovery guide.

What a Half-Matched Transplant Costs in India

A haploidentical bone marrow transplant in India typically costs about $14,000 to $38,000 (USD). The final cost depends on:

• The condition being treated and the conditioning regimen
• The patient’s age and overall health
• Whether desensitization for donor antibodies is needed
• Length of hospital stay and any complications, such as infections or GVHD
• Medicines after discharge, accommodation and the cost of the donor’s evaluation and stay

Ask for a written estimate that clearly states what is included, and plan a financial cushion for the unexpected. You can compare figures on our bone marrow transplant cost in India page.

Questions to Ask Your Transplant Team

• Is a transplant the right treatment for my condition at this stage?
• Which of my family members should be HLA tested, and can testing be done before we travel?
• Have you tested me for donor-specific antibodies against each possible donor?
• Why do you recommend this particular donor?
• How many half-matched transplants have you done for my condition, and what are your results?
• What is my risk of graft failure, GVHD and relapse?
• How long will the patient and the donor need to stay in India?
• What follow-up will I need at home, and who will my doctors contact if problems arise?

Key Takeaways

• Most patients without a matched sibling or registry donor still have a half-matched family donor: a parent, child or sibling.
• Post-transplant cyclophosphamide has made half-matched transplants safer, with survival similar to matched unrelated donors in many blood cancers.
• The best donor is chosen by antibody testing, age, health and relationship, not simply by who is willing.
• Heavily transfused patients, such as those with thalassemia, need a center experienced in preventing graft rejection.
• The donor must travel with the patient. Plan for about three months in India.
• A half-matched transplant in India typically costs about $30,000 to $33,000.

References:

• NMDP
• Blood Advances
• ASTCT Nucleus (2025)
• Cleveland Clinic
• Johns Hopkins Medicine

Recent Blogs

Gunshot and Blast Injuries: Fractures, Spinal Cord Damage and Reconstruction in India

No Matched Donor for a Bone Marrow Transplant? How a Half-Matched Transplant Works

Pituitary Tumor Surgery: Through the Nose or Through the Skull? How Doctors Decide

Gamma Knife, CyberKnife or Open Surgery: Which Brain Tumors Can Be Treated Without Opening the Skull

Diagnosed Early With Cancer? Why Delaying Proven Treatment Can Cost You Your Best Chance